Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

GSK-573719

Generic Name: GSK-573719

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)

Phase 3

Completed

Posted: 2014/07/09

Sponsor:GlaxoSmithKline

ID:NCT02184611

Long-term Safety Study for GSK573719 in Japanese

Phase 3

Completed

Posted: 2012/10/08

Sponsor:GlaxoSmithKline

ID:NCT01702363

Aura Adolescent PK Study GSK2829332

Phase 2

Withdrawn

Posted: 2012/07/31

Sponsor:GlaxoSmithKline

ID:NCT01653483

QTc Study GSK573719+GW642444

Phase 1

Completed

Posted: 2012/01/30

Sponsor:GlaxoSmithKline

ID:NCT01521377

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

Phase 3

Completed

Posted: 2011/07/04

Sponsor:GlaxoSmithKline

ID:NCT01387230

FDA Approved Products

Trelegy Ellipta

Manufacturer:GlaxoSmithKline LLC

Route:RESPIRATORY (INHALATION)

Strength:62.5 ug in 1 1

Approved: 2020/09/09

NDC:0173-0893

Trelegy Ellipta

Manufacturer:GlaxoSmithKline LLC

Route:RESPIRATORY (INHALATION)

Strength:62.5 ug in 1 1

Approved: 2020/09/09

NDC:0173-0887

Incruse Ellipta

Manufacturer:GlaxoSmithKline LLC

Route:ORAL

Strength:62.5 ug in 1 1

Approved: 2020/08/17

NDC:0173-0873

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy